The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
复制标题
DOI：
10.1111/j.1365-2141.2006.06476.x
复制
发表时间：
2007-02-01
影响因子：
6.5
通讯作者：
Kantarjian, Hagop
中科院分区：
文献类型：
--
作者：
Giles, Francis J.;Borthakur, Gautam;Kantarjian, Hagop
造血细胞移植共病指数(HCTCI)预测干细胞移植后无复发死亡率和总存活率(OS)。对177名60岁以上接受急性髓系白血病(AML)诱导治疗的患者进行了HCTCI评分。HCTCI评分为0分者占22%，1~2分者占30%，<3分者占48%。早期死亡率分别为3%、11%和29%，中位OS分别为45周、31周和19周(P=0.001)。HCTCI评分可以预测接受AML诱导治疗的老年患者的早期死亡率和OS。
The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation. HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid leukaemia (AML) induction therapy. HCTCI score was 0 in 22% of patients, 1-2 in 30%, and >= 3 in 48%. In patients with scores of 0, 1-2, or >= 3, early death rates were 3%, 11% and 29% (P < 0.001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy.